Physician

Sidharth Ravi Anand, M.D.

According to 2025 Medicare claims, Sidharth Anand, M.D. (NPI: 1336453810) practices medical oncology in the Oxnard-Thousand Oaks-Ventura, CA market, with the plurality of this provider's patient population coming from Ventura, CA. This provider's primary affiliated billing organization is THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (NPI: 1235107566; TIN: 954373071) and primary practice location at 91361-3705.

Anand's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 555 traditional Medicare patients, billed 125,991 HCPCS/CPT codes, and received $1,870,338 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 1,141 prescription claims across 180 beneficiaries totaling $2,136,846 in drug costs, led by Tibsovo (Ivosidenib). DME data shows 93 claims. Open Payments data shows 8 records totaling $4,983. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $73,933 to $1,870,338. Similarly, Part D prescription costs have moved sharply higher in recent years, from $5,807 to $2,136,846. In contrast, DME billing represents a smaller volume and fell sharply in recent years, from $1,266 to $0.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	283	667	$73,933
2016	76	206	$20,615
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	131	17,947	$170,170
2020	313	50,058	$879,710
2021	429	82,243	$1,344,340
2022	513	119,756	$1,936,209
2023	611	141,427	$2,191,463
2024	555	125,991	$1,870,338

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	35	103	$5,807
2016	15	33	$558
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	29	59	$36,873
2020	62	383	$302,250
2021	88	484	$592,589
2022	115	618	$474,920
2023	183	858	$1,111,438
2024	180	1,141	$2,136,846

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	11	$809
2017	N/R	11	$726
2018	N/R	12	$726
2019	N/R	N/R	N/R
2020	24	75	$7,300
2021	36	108	$10,660
2022	N/R	71	$3,035
2023	40	128	$37,416
2024	N/R	93	$2,499

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	83	149	$150
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	333	793	$102
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	136	179	$72
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	221	725	$8
J7050	Infusion, normal saline solution, 250 cc	62	429	$1

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Tibsovo	Ivosidenib	12	360	$397,453
Xtandi	Enzalutamide	17	510	$246,701
Lenalidomide	Lenalidomide	14	329	$222,081
Imbruvica	Ibrutinib	13	364	$201,049
Eliquis	Apixaban	106	5,734	$109,753

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	43	$1,722
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	26	$489
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	24	$288

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	8	$4,983	Pharmacosmos Therapeutics Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Sidharth Ravi Anand, M.D.?

Tedicare shows public-source Medicare data for Sidharth Ravi Anand, M.D. (NPI 1336453810), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Sidharth Ravi Anand, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Sidharth Ravi Anand, M.D.?

Sidharth Ravi Anand, M.D. is linked to THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (billing NPI 1235107566) in the available physician profile data.

Does Sidharth Ravi Anand, M.D. have Open Payments data?

Sidharth Ravi Anand, M.D. has 8 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.